A microneedle patch for measles vaccination, now in development, could help push global measles vaccine coverage from the current 85% to the 95% needed to interrupt disease transmission. Developed by the CDC and the Georgia Institute of Technology, the microneedle patch is designed to be administered by minimally trained workers and simplifies storage, distribution, and disposal compared with conventional vaccines. A recent study showed the patch produced a strong immune response in rhesus macaques with no adverse effects, paving the way for human clinical trials to begin as early as 2017 (Edens C et al. Vaccine. doi:10.1016/j.vaccine.2015.02.074 [published online March 12, 2015]).
Microneedle Measles Patch Could Boost Global Immunization Coverage. JAMA. 2015;313(22):2214. doi:10.1001/jama.2015.5715